ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

TLRY

7.45

-2.1%↓

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

TLRY

7.45

-2.1%↓

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

TLRY

7.45

-2.1%↓

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

TLRY

7.45

-2.1%↓

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

TLRY

7.45

-2.1%↓

Search

Johnson and Johnson

Fermé

SecteurSoins de santé

227.38 0.01

Résumé

Variation du prix de l'action

24h

Actuel

Min

226.57

Max

227.95

Chiffres clés

By Trading Economics

Revenu

-385M

5.2B

Ventes

571M

25B

P/E

Moyenne du Secteur

20.081

90.422

BPA

2.46

Rendement du dividende

2.33

Marge bénéficiaire

21.473

Employés

138,100

EBITDA

-4.9B

4.4B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+6.38% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.33%

2.13%

Prochains Résultats

14 avr. 2026

Date du Prochain Dividende

10 mars 2026

Date du Prochain Détachement de Dividende

24 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

6.8B

534B

Ouverture précédente

227.37

Clôture précédente

227.38

Sentiment de l'Actualité

By Acuity

26%

74%

57 / 352 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Johnson and Johnson Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 janv. 2026, 16:07 UTC

Résultats

Intuitive Surgical Stock Beats Earnings Estimates. The Stock Is Barely Moving. -- Barrons.com

23 janv. 2026, 12:58 UTC

Résultats

Intuitive Surgical Stock Rises on Earnings. What Wall Street Is Saying. -- Barrons.com

21 janv. 2026, 19:24 UTC

Résultats

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 janv. 2026, 15:31 UTC

Résultats

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 janv. 2026, 12:07 UTC

Résultats

Johnson & Johnson Earnings Beat Estimates. The Stock Is Falling. -- Barrons.com

21 janv. 2026, 11:35 UTC

Résultats

Johnson & Johnson Earnings Beat Estimates. The Stock Is Falling. -- Barrons.com

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson Sees 2026 Adj EPS $11.43-Adj EPS $11.63 >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson 4Q Worldwide MedTech Sales $8.80B >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson: 4Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed and Wound Closure Pdts >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.28-$11.48 >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson: See Higher EPS Growth in Second Half of 2026 Vs First Half >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson: In 2026, Expect Heavy Investment in 1Q Vs Rest of the Year >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson: 4Q Innovative Medicine Operational Sales Grew 5.3%, With Net Acquisitions and Divestitures Positively Affecting Growth by 1.2% Due to Caplyta >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson: With MedTech, Impact of Tariffs Assumed to Be Consistent Throughout 2026 >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson: 4Q Innovative Medicine Operational Sales Growth Was Partially Offset By Impact From Stelara >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson 4Q Worldwide Innovative Medicine Sales $15.76B >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.4%-6.4% >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson 4Q International Sales $10.37B >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson Sees 2026 Operational Sales of $99.5B-$100.5B >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson: 4Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya, Simponi/Simponi Aria and Spravato >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson Sees 2026 Sales $100B-$101B >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson 4Q U.S. Sales $14.2B >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson 4Q Sales $24.56B >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson 4Q Orthopaedics Sales $2.44B >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson 4Q Adj EPS $2.46 >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson 4Q Worldwide Innovative Medicine Sales $15.76B >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson 4Q EPS $2.10 >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson 4Q International Sales $10.37B >JNJ

21 janv. 2026, 11:20 UTC

Résultats

Johnson & Johnson 4Q Worldwide MedTech Sales $8.8B >JNJ

Comparaison

Variation de prix

Johnson and Johnson prévision

Objectif de Prix

By TipRanks

6.38% hausse

Prévisions sur 12 Mois

Moyen 241.75 USD  6.38%

Haut 265 USD

Bas 217 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

13 ratings

9

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

154.93 / 155.895Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

57 / 352Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
help-icon Live chat